References
- HeywoodWPatrickKSmithAMWho gets tattoos? Demographic and behavioral correlates of ever being tattooed in a representative sample of men and womenAnn Epidemiol2012221515622153289
- LauxPTralauTTentschertJA medical-toxicological view of tattooingLancet20163871001639540226211826
- UrdangMMallekJTMallonWKTattoos and piercings: a review for the emergency physicianWest J Emerg Med201112439339822224126
- AdattoMAHalachmiSLapidothMTattoo removalCurr Probl Dermatol2011429711021865802
- ArmstrongMLRobertsAEKochJRSaundersJCOwenDCAndersonRRMotivation for contemporary tattoo removal: a shift in identityArch Dermatol2008144787988418645139
- VarmaSLaniganSWReasons for requesting laser removal of unwanted tattoosBr J Dermatol1999140348348510233271
- HoughtonSJDurkinKParryETurbettYOdgersPAmateur tattooing practices and beliefs among high school adolescentsJ Adolesc Health19961964204258969374
- MoedLShwayderTAChangMWCantharidin revisited: a blistering defense of an ancient medicineArch Dermatol2001137101357136011594862
- HoSGGohCLLaser tattoo removal: a clinical updateJ Cutan Aesthetic Surg201581915
- BaumlerWLaser treatment of tattoos: basic principlesCurr Probl Dermatol2017529410428288450
- JakusJKailasAPicosecond lasers: a new and emerging therapy for skin of color, minocycline-induced pigmentation, and tattoo removalJ Clin Aesthet Dermatol201710141528360964
- RamsayJRSuhrbierAAylwardJHThe sap from Euphorbia peplus is effective against human nonmelanoma skin cancersBr J Dermatol2011164363363621375515
- OgbourneSMSuhrbierAJonesBAntitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell deathCancer Res20046482833283915087400
- AlchinDRIngenol mebutate: a succinct review of a succinct therapyDermatol Ther201442157164
- BermanBSafety and tolerability of ingenol mebutate in the treatment of actinic keratosisExpert Opin Drug Saf201514121969197826524598
- LebwohlMSwansonNAndersonLLMelgaardAXuZBermanBIngenol mebutate gel for actinic keratosisN Engl J Med2012366111010101922417254
- CozziSJOgbourneSMJamesCIngenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patchesJ Invest Dermatol201213241263127122189786
- KedeiNLundbergDJTothAWelburnPGarfieldSHBlumbergPMCharacterization of the interaction of ingenol 3-angelate with protein kinase CCancer Res20046493243325515126366
- ErlendssonAMKarmisholtKEHaakCSStenderIMHaedersdalMTopical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): a randomized clinical trialJ Am Acad Dermatol201674470971526810403
- SillerGRosenRFreemanMWelburnPKatsamasJOgbourneSMPEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trialAustralas J Dermatol20105129910520546215
- LewohlMSohnAIngenol mebutate (ingenol 3-angelate, PEP005): focus on its uses in the treatment of nonmelanoma skin cancerExpert Opin Drug Saf201272121128
- LeTTSkakKSchroderKIL-1 contributes to the anti-cancer efficacy of ingenol mebutatePloS One2016114e015397527100888
- LiLShuklaSLeeAThe skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculatureCancer Res201070114509451920460505
- ChallacombeJMSuhrbierAParsonsPGNeutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelateJ Immunol2006177118123813217114487
- CozziSJLeTTOgbourneSMJamesCSuhrbierAEffective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 miceArch Dermatol Res20133051798322871992
- SchroderWAAnrakuILeTTSerpinB2 deficiency results in a stratum corneum defect and increased sensitivity to topically applied inflammatory agentsAm J Path201618661511152327109612
- SolisRRDivenDGColome-GrimmerMISnyderNtWagnerRFJrExperimental nonsurgical tattoo removal in a guinea pig model with topical imiquimod and tretinoinDermatol Surg20022818386 discussion 86–8711998793
- ClabaughWATattoo removal by superficial dermabrasion. Five-year experiencePlast Reconstr Surg19755544014051118499
- ClabaughWRemoval of tattoos by superficial dermabrasionArch Dermatol19689855155215684226
- ElsaieMLNouriKVejjabhinantaVTopical imiquimod in conjunction with Nd:YAG laser for tattoo removalLasers Med Sci200924687187519597914
- DeChateletLRShirleyPSJohnstonRBJrEffect of phorbol myristate acetate on the oxidative metabolism of human polymorphonuclear leukocytesBlood19764745455541260119
- Wang-IversonPPryzwanskyKBSpitznagelJKCooneyMHBactericidal capacity of phorbol myristate acetate-treated human polymorphonuclear leukocytesInfect Immun1978223945955730386
- AlfakryHMalleEKoyaniCNPussinenPJSorsaTNeutrophil proteolytic activation cascades: a possible mechanistic link between chronic periodontitis and coronary heart diseaseInnate Immun2016221859926608308
- LemperleGMorhennVBPestonjamaspVGalloRLMigration studies and histology of injectable microspheres of different sizes in micePlast Reconstr Surg200411351380139015060350
- RamirezMMageeNDivenDTopical imiquimod as an adjuvant to laser removal of mature tattoos in an animal modelDermatol Surg200733331932517338690
- RicottiCAColacoSMShammaHNTrevinoJPalmerGHeaphyMRJrLaser-assisted tattoo removal with topical 5% imiquimod creamDermatol Surg20073391082109117760599
- SepehriMJorgensenBSerupJIntroduction of dermatome shaving as first line treatment of chronic tattoo reactionsJ Dermatolog Treat20152645145525672517